Evidence map›Paper›PMID 37467430›Full record

ArticleJournal of medicinal chemistry2023

Pharmacological and Physicochemical Properties Optimization for Dual-Target Dopamine D

Alessandro Bonifazi, Elizabeth Saab, Julie Sanchez, Antonina L Nazarova, Saheem A Zaidi, Khorshada Jahan, Vsevolod Katritch, Meritxell Canals, J Robert Lane, Amy Hauck Newman

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of medicinal chemistry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Dual-target mu opioid-dopamine DEuropean journal of medicinal chemistry · 2026
    Article
  2. Article
  3. Rational Design Biased Compounds against μ‑Opioid Receptor.ACS pharmacology & translational science · 2025
    Article
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Alessandro BonifaziMedicinal Chemistry Section, Molecular Targets and Medications Discovery Branch, National Institute on Drug Abuse─Intramural Research Program, National Institutes of Health, 333 Cassell Drive, Baltimore, Maryland 21224, United States.ORCID 0000-0002-7306-0114
Elizabeth SaabMedicinal Chemistry Section, Molecular Targets and Medications Discovery Branch, National Institute on Drug Abuse─Intramural Research Program, National Institutes of Health, 333 Cassell Drive, Baltimore, Maryland 21224, United States.
Julie SanchezDivision of Physiology, Pharmacology and Neuroscience, School of Life Sciences, Queen's Medical Centre, University of Nottingham, Nottingham NG7 2UH, U.K.
Antonina L NazarovaDepartment of Quantitative and Computational Biology, Department of Chemistry, Dornsife Center for New Technologies in Drug Discovery and Development, Bridge Institute, Michelson Center for Convergent Biosciences, University of Southern California, Los Angeles, California 90089, United States.
Saheem A ZaidiDepartment of Quantitative and Computational Biology, Department of Chemistry, Dornsife Center for New Technologies in Drug Discovery and Development, Bridge Institute, Michelson Center for Convergent Biosciences, University of Southern California, Los Angeles, California 90089, United States.
Khorshada JahanMedicinal Chemistry Section, Molecular Targets and Medications Discovery Branch, National Institute on Drug Abuse─Intramural Research Program, National Institutes of Health, 333 Cassell Drive, Baltimore, Maryland 21224, United States.
Vsevolod KatritchDepartment of Quantitative and Computational Biology, Department of Chemistry, Dornsife Center for New Technologies in Drug Discovery and Development, Bridge Institute, Michelson Center for Convergent Biosciences, University of Southern California, Los Angeles, California 90089, United States.ORCID 0000-0003-3883-4505
Meritxell CanalsDivision of Physiology, Pharmacology and Neuroscience, School of Life Sciences, Queen's Medical Centre, University of Nottingham, Nottingham NG7 2UH, U.K.ORCID 0000-0002-7942-5006
J Robert LaneDivision of Physiology, Pharmacology and Neuroscience, School of Life Sciences, Queen's Medical Centre, University of Nottingham, Nottingham NG7 2UH, U.K.ORCID 0000-0002-7361-7875
Amy Hauck NewmanMedicinal Chemistry Section, Molecular Targets and Medications Discovery Branch, National Institute on Drug Abuse─Intramural Research Program, National Institutes of Health, 333 Cassell Drive, Baltimore, Maryland 21224, United States.ORCID 0000-0001-9065-4072
National Institutes of Health · USUniversity of Southern California · USWest Midlands Deanery · GB

Funding

Novel Dopamine D3 Receptor Ligands ZIADA000424 · NIDA · NATIONAL INSTITUTE ON DRUG ABUSE · PI NEWMAN, AMY HAUCK · 2009 to 2025
$25.9M
Dopamine D2-like Functionally Selective AgonistsZIADA000609 · NIDA · NATIONAL INSTITUTE ON DRUG ABUSE · PI NEWMAN, AMY HAUCK · 2016 to 2020
$2.8M
Efficient synthon-based modular screening of Giga-to-Terra-scale virtual librariesR01GM147537 · NIGMS · UNIVERSITY OF SOUTHERN CALIFORNIA · PI KATRITCH, VSEVOLOD · 2022 to 2024
$1.2M
Intramural NIH HHS ZIA DA000424Intramural NIH HHS ZIA DA000609NIGMS NIH HHS R01 GM147537
6 · The paper itself

Abstract

A new generation of dual-target μ opioid receptor (MOR) agonist/dopamine D

Indexed as

Analgesics, OpioidOpioid-Related DisordersAnalgesicsDopamineHumansLigandsReceptors, Dopamine D3Receptors, Opioid, muAnalgesicsAnalgesics, OpioidDopamineLigandsReceptors, Dopamine D3Receptors, Opioid, mu

Identifiers

PMID37467430
PMCPMC11091828
OpenAlexW4384817578

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.